Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers

Crucell

Status and phase: Completed; Phase 3

Conditions: Influenza

Treatments: Biological: Virosomal influenza vaccine (CSL HA Antigen); Biological: Virosomal influenza vaccine (AdImmune HA Antigen)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01412281

ADD-V-A002

Details and patient eligibility

About

The purpose of this study is to assess the humoral immune response and safety of the parenteral formulation of the 2010/2011-season virosomal subunit influenza vaccine Inflexal V using two different HA antigen suppliers (AdImmune and CSL), in groups of young and elderly adults, using the EMA (European Medicines Agency) regulation as a guideline.

Enrollment: 440 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy female and male adults
• Aged ≥18 years on Day 1
• Written informed consent

Exclusion criteria

• Acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or other acute disease
• Acute febrile illness (≥38.0 °C)
• Prior vaccination with an influenza vaccine (including the H1N1 pandemic swine flu vaccine) in the past 330 days
• Known hypersensitivity to any vaccine component
• Previous history of a serious adverse reaction to influenza vaccine
• History of egg protein allergy or severe atopy
• Known blood coagulation disorder
• Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of the study vaccine, incl. oral corticosteroids in dosages of ≥0.5 mg/kg/d prednisolone or equivalent (inhaled or topical steroids are allowed)
• Known immunodeficiency (incl. leukemia, cancer, HIV seropositivity)
• Investigational medicinal product received in the past 3 months (90 days)
• Treatment with immunoglobulins or blood transfusion(s) received in the past 3 months (90 days)
• Pregnancy or lactation
• Participation in another clinical trial
• Employee at the investigational site, or spouse and children of the investigator, or relative living in the same household as the investigator and/or are dependent on the investigator
• Suspected non-compliance

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

440 participants in 4 patient groups

Group A - Young adults

Experimental group

Description:

1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012

Treatment:

Biological: Virosomal influenza vaccine (AdImmune HA Antigen)

Group B - Young adults

Active Comparator group

Description:

1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012

Treatment:

Biological: Virosomal influenza vaccine (CSL HA Antigen)

Group C - Elderly

Experimental group

Description:

1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012

Treatment:

Biological: Virosomal influenza vaccine (AdImmune HA Antigen)

Group D - Elderly

Active Comparator group

Description:

1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012

Treatment:

Biological: Virosomal influenza vaccine (CSL HA Antigen)